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A B S T R A C T
The infection with Human papillomavirus (HPV) is the necessary cause for cervical cancer. There are at least 15
High-Risk (HR) HPV types that are significantly associated with progression of cervical intraepithelial neoplasia to cer-
vical cancer. Since previous studies showed that the prevalence of HPV in cervical cancers varies among different geo-
graphic regions, we wanted to investigate the prevalence of HPV types in Croatia, especially low abundant HR HPV
types. By means of consensus primers directed polymerase chain reaction (PCR), we analysed cervical DNA samples of
2,136 Croatian women, mostly with abnormal cervical smears, in order to detect the presence of HPV. Type-specific prim-
ers were then used to determine Low-Risk (LR) HPV types 6/11 and HR HPV types 16, 18, 31, 33, 45, 52 and 58. Out of
2,136 specimens, 1,255 (58.8%) were positive for HPV. More than half of positive samples were typed (64.5%) and 35.5%
still remained untyped. Multiple HPV infections were found in 10.3% of the cases. The most prevalent type, including
both single and multiple infections, was HPV 16 with the prevalence of 15.9%, followed by HPV types 31, 6/11, 33, 18, 52,
45 and 58 with 8.7%, 7.1%, 4.5%, 3.8%, 2.3%, 1.2% and 1.1%, respectively. The significant increase of frequency from
Low-grade Squamous Intraepithelial Lesions (LSIL) to High-grade Squamous Intraepithelial Lesions (HSIL) was ob-
served for HR HPV types 16, 18, 31 and 33 but not 45, 52 and 58. The frequency of unknown HPV types was almost the
same in cervical specimens of women with LSIL and those with HSIL, 19.8% and 21.1%, respectively. The prevalence of
HPV infection rate decreased significantly with patient age from 68.5% (age group 12 to 24 years) to 38.8% (age group 45
to 54 years). But, in women aged 55 or older the overall prevalence increased to 56.6%. Our results indicate that preva-
lence of HR HPV types in Croatia is similar to other countries. We suggest that HPV positive women in Croatia should be
closely monitored by typing for HR HPV types: 16, 18, 31, 33, 45, 52 and 58.
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Introduction
Cervical cancer is the second most common malig-
nancy after breast cancer among women worldwide.
More than 80% of cases occur in developing countries. In
2002, about 493,000 cervical cancer cases (incidence rate
16/100,000) and about 273,000 deaths from cervical can-
cer (mortality rate 8.9/100,000), respectively, were re-
corded worldwide1. The incidence and mortality rates in
Croatia in 2002 represents the intermediate value of the
highest and lowest rates noted in Europe, with 431 cases
(incidence rate 18/100,000) and 209 deaths (mortality
rate 8.7/100,000) from cervical cancer, respectively2,3.
This indicates that cervical cancer represents a major
health concern in Croatia that needs to be improved.
Epidemiological studies have clearly established hu-
man papillomavirus (HPV) infection as the prerequisite
for cervical cancer4. Studies in 22 countries coordinated
by the International Agency for Research on Cancer
(IARC), identified HPV DNA in almost all (99.7%) of
about 1,000 cases of cervical cancer5. To date, more than
200 different HPV types have been recognized on the ba-
sis of DNA sequence data6. More than 100 HPV geno-
types are well characterized7. Over 40 types infect the
human anogenital area, of which some can cause genital
warts and others can lead to precursor cervical lesions,
CIN (cervical intraepithelial neoplasia) and cervical
cancer7. At least 15 HPV types are significantly associ-
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ated with progression of CIN to cervical cancer and are
considered carcinogenic and named High-Risk (HR)
HPV types8. Thus, HPV 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68, 73 and 82 were classified as HR or carcino-
genic types, HPV 26, 53 and 66 as probable carcinogenic
types, while HPV 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81
and CP6108 as Low-Risk (LR)8. In contrast to HR HPV
types, LR types are associated with benign genital warts
and only occasionally found in cervical carcinomas. Ac-
cording to the epidemiological and the phylogenetic stud-
ies, most HR HPV types associated with lesions of simi-
lar pathologies are phylogenetically related to either
HPV 16 (31, 33, 35, 52 and 58) or HPV 18 (39, 45, 59 and
68)7.
The prevalence of HPV types in cervical cancers var-
ies among different geographic areas4,9–10. In a worldwide
survey, HPV 16 was found to be the most prevalent type
in cervical cancer (51.0%), followed by HPV 18 (16.2%)
and other types such as HPV 45, 31, 33, 58 and 52 (collec-
tively accounting for 18.3% cases)4. In Europe, beside
HPV 16, types 18, 33, 31 and 45 were the most frequently
found HR HPV types in cervical cancer4. Infection with
HPV 45 was found to be third most frequent in Africa, af-
ter HPV 16 and 18. HPV 52 and 58 are less frequent in
Europe, but not uncommon worldwide, especially in Asia,
being the most frequently found HR HPV types after 16
and 184.
There is limited data regarding the prevalence of low
abundant HR HPV types in Croatia. Therefore, the aim
of this study was to evaluate the prevalence of HR HPV
types 45, 52 and 58 among Croatian women on the archi-
val DNA samples where HPV types 6/11, 16, 18, 31 and
33 were previously determined11,12.
Material and Methods
Study population
Two thousand one hundred and thirty six Croatian
women, mostly with abnormal cervical smears, were en-
rolled in this study. The cervical specimens for HPV detec-
tion and typing were collected in different gynaecological
hospital clinics in Zagreb, Croatia11,12. The cytological
diagnosis13 of the study population consisted of 0.7% (15/2,
136) normal Pap smears, 24.8% (529/2,136) ASCUS (atyp-
ical squamous cells of undetermined significance), 28.8%
(615/2,136) LSIL (Low-grade Squamous Intraepithelial
Lesions) and 40.9% (874/2,136) HSIL (High-grade Squa-
mous Intraepithelial Lesions). Furthermore, there were
4.8% (103/2,136) women with unknown cytological diag-
nosis.
DNA preparation
DNA from cervical cell samples was isolated as de-
scribed previously11,12. Briefly, cervical cell suspensions
were collected and treated with proteinase K (100 µg/ml
in lysis buffer, 10 mM Tris-HCl; pH 7.5, 1 mM EDTA, pH
7.9; 0.5% SDS) overnight at 37°C or 2h at 56°C. Standard
phenol-chloroform extraction and ethanol precipitation
were used for DNA purification. Pelleted DNA was resus-
pended in 50–100 L of deionised sterile water and
stored at –20°C until further analysis14. In order to deter-
mine the quality and the quantity of isolated DNA, each
DNA was analysed by electrophoresis on 1% agarose gels
stained with ethidium bromide and spectrophotomet-
rically14.
HPV detection and typing
Cervical DNA samples were tested for the presence of
HPV DNA by PCR based method as previously des-
cribed11,12–15. Briefly, two sets of consensus primers: MY09/
MY11, degenerated primers, and L1C1/L1C2-1/L1C2-2
primers were used for HPV DNA detection. To internally
control the quality of the target DNA and the absence of
PCR inhibitors, -globin specific primers were used in
the multiplex PCR with MY09/MY11 primers. Type-spe-
cific primers for HPV 6/11, 16, 18, 31 and 33 were also
used in two separate multiplex PCRs, i.e. HPV 6/11 with
31 and HPV 16, 18 with 33. All amplification reactions
were performed on 100 ng of each DNA in a total volume
of 20 l under the optimized conditions as previously
described11,12–15.
In this study, archival DNA samples were additionally
examined for the presence of HPV 45, 52 and 58 with
type-specific primers directed PCR, also 5,16. The reaction
mixtures contained 10 mMTris-HCl, pH 8.3, 50 mMKCl,
1.5 mM MgCl2, 100 M of each dNTP, 0.15 M of each
type-specific primer, 0,12 U AmpliTaq Gold DNA Poly-
merase (Roche) and 100 nm of each DNA in a total vol-
ume of 20 l. The amplification conditions for HPV 52
and 58 consisted of 30 cycles of denaturation at 95°C for
30 sec, annealing at 56°C for 30 sec and extension at 72°C
for 30 sec, while for HPV 45 it consisted of 35 cycles of de-
naturation at 95°C for 40 sec, annealing at 55°C for 40 sec
and extension at 72°C for 45 sec, with in both cases an
initial denaturation at 95°C for 10 min and a final exten-
sion of 7 min.
Aliquots (10 l) of each PCR product were resolved by
electrophoresis in a 2% agarose gel stained with ethi-
dium bromide14. The amplified products were identified
by UV irradiation of the gels, and photographed by Im-
age Master VDS (Pharmacia Biotech).
Statistical analysis
The standard Chi-square (c2) test was used. Two-
-tailed p values were calculated in 2 x 2 tables using the
GraphPad Prism (version 4.00) (GraphPad Software,
San Diego, California). All tests were two sided and the
significance level was set at p  0.0517.
Results
The average age of the study population was 30.6
(ranging from 12 to 75 years of age). The distribution of
patient cytological diagnosis according to patient age is
shown in Figure 1.
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Distribution of different HPV types
All DNA specimens prepared from cervical cell sam-
ples were -globin positive and as such suitable for fur-
ther HPV DNA detection and typing by PCR. Out of
2,136 DNA samples, 1,255 (58.8%) were positive for any
HPV type (Tables 1 and 2).
More than half (64.5%) of HPV positive samples were
typed. In 445 (35.5%) samples HPV type was not deter-
mined (HPV X). Multiple HPV infections with two or more
HPV types were found in 10.3% (129/1,255) of the cases,
mainly among younger women (mean age 26) (Table 2).
LR HPVs (types 6 or 11) appeared as single infections
only in 4.9% (104/2,136) cases. Among HR HPVs, type 16
was the most frequently found as single infection in
11.9% (254/2,136) of the cases, followed by HPV types 31,
33, 18, 52, 45 and 58 found in 5.7% (121/2,136), 2.8%
(60/2,136), 2.6% (55/2,136), 2.2% (46/2,136), 1.0% (22/2,
136), and 0.9% (19/2,136) of the cases, respectively (Ta-
bles 1 and 2).
Out of 129 multiple HPV infections (Table 3), there
were 82 (63.6%) co-infections of two or three HR HPVs
and 47 (36.4%) co-infections of LR HPV (type 6 or 11)
and one or two HR HPV types. The co-infection of HPV
types 16 and 31 or 16 and 6/11 were the most frequent,
present in 25.6% (33/129) and 19.4% (25/129) cases, re-
spectively.
Prevalence of different HPV types
HPV 16 was present in 85 multiple infections and in
254 single infections, which increases the total preva-
lence of HPV 16 in the study population to 15.9% (339/2,
136). HPV 31 was the second most frequent HPV type,
being represented in 65 multiple infections and 121 sin-
gle infections, with a final prevalence of 8.7% (186/2,136)
(Figure 2). The prevalence, including both single and
multiple infections, of HPV types 6/11, 18, 33, 45, 52 and
58 was 7.1% (151/2,136; not shown), 3.8% (82/2,136),
4.5% (95/2,136), 1.2% (25/2,136), 2.3% (49/2,136) and
1.1% (23/2,136), respectively (Figure 2).
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Fig. 1. Distribution of patient diagnosis according to patient age.
ASCUS – atypical squamous cells of undetermined significance,
LSIL – low-grade squamous cell intraepithelial lesion, HSIL –
high-grade squamous cell intraepithelial lesion.
TABLE 1
HPV TYPE SPECIFIC PREVALENCE IN THE GROUP OF PATIENTS WITH DIFFERENT CYTOLOGICAL FINDINGS
HPV
type
Cytological diagnosis
Total
Unknown Normal ASCUS LSIL HSIL
N % N % N % N % N % N %
HPV 6/11 5 4.9 0 0.0 29 5.5 29 4.7 41 4.7 104 4.9
HPV 16 10 9.7 0 0.0 49 9.3 46 7.5 149 17.1 254 11.9
HPV 18 3 2.9 0 0.0 8 1.5 13 2.1 31 3.6 55 2.6
HPV 31 5 4.9 0 0.0 26 4.9 21 3.4 69 7.9 121 5.7
HPV 33 3 2.9 0 0.0 7 1.3 15 2.4 35 4.0 60 2.8
HPV 45 0 0.0 0 0.0 8 1.5 6 1.0 8 0.9 22 1.0
HPV 52 1 1.0 0 0.0 15 2.8 11 1.8 19 2.2 46 2.2
HPV 58 0 0.0 0 0.0 3 0.6 7 1.1 9 1.0 19 0.9
Any HR 22 21.4 0 0.0 116 21.9 119 19.4 320 36.6 577 27.0
HPV X 17 16.5 3 20.0 119 22.5 122 19.8 184 21.1 445 20.8
Multiple 7 6.8 1 6.7 22 4.2 28 4.6 71 8.1 129 6.0
Positive 51 49.5 4 26.7 286 54.1 298 48.5 616 70.5 1,255 58.8
Negative 52 50.5 11 73.3 243 45.9 317 51.5 258 29.5 881 41.3
Total 103 4.8 15 0.7 529 24.8 615 28.8 874 40.9 2,136 100
ASCUS – atypical squamous cells of undetermined significance, LSIL – low grade squamous cell intraepithelial lesion, HSIL – high
grade squamous cell intraepithelial lesion, HPV – human papillomavirus, HR – high-risk, HPV X –unknown HPV type
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Prevalence of HR HPV types in HSIL
When both single and multiple infections are included
HPV 16 was present in 23% (201/874) of HSIL samples
HPV types 31, 33, 18, 52, 58 and 45 were found in 12.0%
(105/874), 6.1% (53/874), 5.0% (44/874), 2.3% (20/874),
1.1% (10/874) and 0.9% (8/874) of the cases, respectively
(Figure 3).
HPV distribution according to patient diagnosis
The prevalence of HPV increased significantly (c2 =
74, d.f. = 1, p < 0.0001) from 48.5% to 70.5% with the se-
verity of cytological findings (Table 1 and Figure 4).
While LR HPV types 6/11 were equally distributed
among LSIL (4.7%) and HSIL (4.7%), HR HPVs were al-
most two times more frequent in HSIL (36.6%) than in
LSIL (19.4%) (for presence of any HR HPV, c2 = 51.75,
d.f. = 1, p < 0.0001). HPV type 16, as a single infection,
was the most frequent, found in 7.5% of cases in LSIL
compared to 17.1% in HSIL (c2 = 29.0, d.f. = 1, p <
0.001). Multiple HPV infections were also two times
more frequent in HSIL than in LSIL, 8.1% and 4.6%, re-
spectively. The frequency of unknown HPV types (HPV
X) was almost the same in cervical specimens of women
with LSIL and those with HSIL, 19.8% and 21.1%, re-
spectively.
HPV distribution according to patient age
The frequency of HPV infections decreased signifi-
cantly (c2 = 94.2, d.f. = 4, p < 0.0001) with patient age
from 68.5% (age group 12 to 24 years) to 38.8% (age
group 45 to 54 years) (Table 2 and Figure 5). But, the
prevalence of HPV in women aged 55 or older increased
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TABLE 2
HPV TYPE SPECIFIC PREVALENCE BY AGE
HPV type
Age group (years)
Total
Unknown 12–24 25–34 35–44 45–54 ³55
N % N % N % N % N % N % N %
HPV 6/11 5 8.6 44 6.4 33 4.2 9 2.4 10 5.6 3 5.7 104 4.8
HPV 16 11 19.0 97 14.0 96 12.3 35 9.4 9 5.1 6 11.3 254 11.9
HPV 18 2 3.5 16 2.3 27 3.5 5 1.3 3 1.7 2 3.8 55 2.6
HPV 31 3 5.2 55 8.0 42 5.4 14 3.7 4 2.3 3 5.7 121 5.7
HPV 33 1 1.7 25 3.6 20 2.6 9 2.4 3 1.7 2 3.8 60 2.8
HPV 45 0 0.0 3 0.4 13 1.7 5 1.3 1 0.6 0 0.0 22 1.0
HPV 52 1 1.7 11 1.6 23 2.9 6 1.6 5 2.8 0 0.0 46 2.2
HPV 58 0 0.0 7 1.0 9 1.2 2 0.5 0 0.0 1 1.9 19 0.9
Any HR 18 31.0 214 30.9 230 29.5 76 20.3 25 14.0 14 26.4 577 27.0
HPV X 13 22.4 153 22.1 164 21.0 72 19.3 31 17.4 12 22.6 445 20.8
Multiple 3 5.2 63 9.1 53 6.8 6 1.6 3 1.7 1 1.9 129 6.0
Positive 39 67.2 474 68.5 480 61.5 163 43.6 69 38.8 30 56.6 1,255 58.8
Negative 19 32.8 218 31.5 301 38.5 211 56.4 109 61.2 23 43.4 881 41.3
Total 58 2.7 692 32.4 781 36.6 374 17.5 178 8.3 53 2.5 2,136 100
HPV – human papillomavirus, HR – high-risk, HPV X – presence of unknown HPV type
TABLE 3
MULTIPLE HPV INFECTIONS
HPV types Cases (N) %
16, 31 33 25.6
6/11, 16 25 19.4
16, 33 14 10.9
18, 31 11 8.5
6/11, 31 7 5.4
31, 33 6 4.7
6/11, 18 5 3.9
6/11, 33 5 3.9
16,18 4 3.1
16, 31, 33 3 2.3
18, 33 2 1.6
45, 52 2 1.6
6/11, 31, 33 2 1.6
16, 18, 31 2 1.6
16, 58 1 0.8
33, 58 1 0.8
45, 58 1 0.8
52, 58 1 0.8
6/11, 16, 18 1 0.8
6/11,16, 31 1 0.8
6/11, 18, 33 1 0.8
16, 18, 33 1 0.8
Total 129 100
HPV – human papillomavirus
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to 56.6%. The observed trend is statistically significant
for HPV 16 (c2 = 10, d.f. = 1, p = 0.0013), HPV 31 (c2 =
10, d.f. = 1, p = 0.0013), presence of any HR HPV (c2 =
22, d.f. = 1, p < 0.0001) and presence of multiple infec-
tion (c2 = 28, d.f. = 1, p < 0.0001).
Discussion
This study was designed to investigate the prevalence
of low abundant HRHPV types 45, 52 and 58 among Cro-
atian women. We analysed archival DNA samples from
2,136 cervical specimens collected from Croatian women
that were previously tested for the presence of LR HPV
types 6 or 11 and HRHPV types 16, 18, 31 and 3311,12,15.
The overall detection of HPV was 58.8%. Out of 1,255
positive samples, 64.5% were typed and in 35.5% of sam-
ples the type was not determined. Those samples gave
positive results with general primers, but they were neg-
ative with type-specific primers used in this study.
The geographic variation of the distribution of differ-
ent HPV types is well established in some regions4,18–20.
Worldwide, in squamous cell carcinoma HPV 16 was the
most prevalent type varying from 46% in Asia to 63% in
Europe, while HPV 18 was the second most common
HPV type. HPV 33, 31 and 45 in Europe and HPV 45 in
Africa were the third HPV types most frequently associ-
ated to cervical squamous cell carcinoma. HR HPV 58 and
52 were found to be less frequent in Europe, but not un-
common worldwide, especially in Asia, where these two
types took the third and fourth place after HPV 16 and 18.
Herein, we found that HPV 16 was the most preva-
lent type among Croatian women, as expected, and it was
present in 15.9% cases of both single and multiple HPV
infections. HPV 31 was the second most prevalent HPV
type appearing in 8.7% both single and multiple HPV in-
fections, followed by HR HPVs 33, 18, 52, 45 and 58 (Fig-
ure 2). The distribution of HR HPV types in the precan-
cerous lesions is slightly different than those in cervical
cancer cases. According to a meta-analysis of Clifford et
al.21 overall HPV prevalence was higher in squamous cell
carcinoma of the cervix (SCC) than in HSIL, 87.6% ver-
sus 84.2%, respectively (SCC : HSIL ratio 1.04). HPV 16
was found to be the most common type in both SCC
(54.3%) and HSIL (45.0%), with a ratio of 1.21. HPV 18
was also more prevalent in SCC (12.6%) than in HSIL
(7.0%), with a ratio of 1.79. Interestingly, HPV 45 was
the third type with a higher ratio (1.85) than those ob-
served with HPV 16 and 18. It was also more frequent in
SCC (4.2%) than in HSIL (2.3%). All other analysed HR
HPVs (including HPV 31, 33, 52 and 58) had ratios less
than 1, i.e. between 0.1 and 0.621. These results suggested
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Fig. 3. Prevalence of specific high-risk human papillomavirus
(HPV) types including single and multiple infections in high-
-grade squamous cell intraepithelial lesion (HSIL) samples.
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Fig. 4. Prevalence of human hapillomavirus (HPV) types including
single and multiple infections according to cytological diagnosis.
Unknown – diagnosis not known, ASCUS – atypical squamous
cells of undetermined significance, LSIL – low-grade squamous
cell intraepithelial lesion, HSIL – high-grade squamous cell
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Fig. 5. Age dependent prevalence of human hapillomavirus (HPV)
types including single and multiple infections.
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Fig. 2. Prevalence of specific high-risk human hapillomavirus
(HPV) types including single and multiple infections in the whole
study population.
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that HSIL, when associated with HPV 16, 18 or 45 is more
likely to progress to SCC than HSIL associated with other
HR HPV types10,21. This evidence pointed out that women
infected with HPV 16, 18 or 45 may require closer surveil-
lance than women infected with other HR HPV types.
When we compared our prevalence analysis of HR
HPV types in HSIL (including both single and multiple
infections) with a worldwide meta-analysis of Clifford et
al.21, we found some discrepancies (Figure 3). HPV 16
was, as expected, the most frequently found type in HSIL
samples in both studies but with almost twice lower
prevalence in our study than those of Clifford et al., 23%
and 45%, respectively. Similarly in both studies, HPV 31
was on the second place with the prevalence of 12.0% in
our study versus 8.8% in Clifford et al. study. HPV 33, fol-
lowed these two HPV types in both studies with, in this
case, similar prevalence of 6.1% in this study and 7.2% in
Clifford et al. study. Further, we found slightly lower inci-
dence of HPV 18 in HSIL samples, in 5.0% cases versus
7.1%. The major discrepancy was the prevalence of HPV
58. While it was rather frequently found type (6.9%) in
Clifford et al. study, we found much lower incidence
among Croatian women (1.1%). We also noticed unex-
pected low prevalence for HPV 52 (2.3%) and HPV 45
(0.9%) compared to Clifford et al. study (5.2% and 2.3%,
respectively). These discrepancies could be explained by
(1) low number of analysed samples in this study, (2) dif-
ferent determination of cytological diagnosis HSIL13, (3)
the choice of primers sets for type-specific HPV ampli-
fication5,12,16 or (4) our data represent a real picture of HPV
prevalence among Croatian women. However, these obser-
vations clearly point out that further analysis with larger
number of samples and alternative method of typing need
to be carried out in the future to clarify this dilemma.
Herein, we found a strong correlation between the
distribution of HR HPV infections and the severity of
cervical lesions, i.e. the frequency of HR HPVs (type 16,
18, 31 and 33) increased with increasing severity of
squamous intraepithelial lesions-SIL, from 19.4% in
LSIL to 36.6% in HSIL (c2 = 74, d.f. = 1, p < 0.0001).
HPV 16 is the most predictive virus type of SIL and it is
present in 7.5% cases of LSIL and 17.1% cases of HSIL
(c2 = 29, d.f. = 1, p < 0.0001). This result is not surpris-
ing, and matches data found in previous reports22,23–24.
The progression from LSIL to HSIL is strongly associ-
ated with the presence of HRHPVs, while no progression
is associated with the presence of LR HPV types or the
absence of HPV25, which further stresses the importance
of HPV DNA typing.
The frequency of unknown HPV types (HPV X) was
approximately the same in cervical swabs of women with
LSIL and those with HSIL, 19.8% versus 21.1%, respec-
tively. Although type-specific primers that we used in
this study were detecting mainly group of HR HPV types
expected in Europe, we would like to continue our study
and determine the unknown HPV types11,12.
In this study, all 129 multiple HPV infections con-
tained at least one HR HPV type. There were 63.6%
co-infections of two or three HR HPV types, while 36.4%
co-infections of LR and HR HPV types (Table 3). The
co-infection of HPV types 16 and 31 was most frequently
found followed by the co-infection of HPV 16 and 6/11.
The frequency of co-infections follows the frequency of
individual HPV types found in the study population (Fig-
ures 2 and 3). HPV types 45, 52 and 58 were rarely found
in multiple infections.
Herein, multiple infections were two times more fre-
quent in HSIL than in LSIL, 8.1% versus 4.6%, what is
not surprising because multiple HPV infections were
mainly represented by co-infections of two or three HR
HPVs or HR- and LR HPVs. In the similar study popula-
tion in Taiwan, Chang et al.26 found adverse results, i.e.
decreasing frequency of multiple HPV infections with in-
creasing severity of cervical lesions. However, a similar
decrease of multiple infection frequency can be observed
from CIN 2 to CIN 3, if the HSIL category is classified ac-
cordingly to the Croatian classification of cervical sme-
ars13 (data not shown). In both cases, the HPV infections
associated with LSIL still represents transient infec-
tions, while the HPV infections associated with HSIL, es-
pecially CIN 3 most probably persistent infections27.
In this study, the frequency of HPV infections de-
creased significantly (c2 for trend = 72.42, d.f. = 1, p <
0.0001) with patient age. Women under the age of 24
years exhibited the highest rate of HPV infections (68.5%),
while women between 45 and 54 years of age exhibited
the lowest rate of HPV infections (38.8%). Multiple HPV
infections were also found mainly among younger wo-
men (mean age 26). This trend of high prevalence in
young age after the beginning of sexual activity and then
a steady decline in subsequent age group is observed in
other studies27. In this study, an increase of HPV preva-
lence in women aged 55 or older to 56.6% was also ob-
served. This trend of gradual fall and then increase in
older age has been observed for any HR HPV, particularly
HPV 16, HPV 18, 31 and 33 but not 45, 52 and 58, and
multiple HPV infections (Table 2 and Figure 5). Interest-
ingly, HPV 45 and 52 were not found among women ³ 55,
while HPV 58 was found mostly in the age group ³ 55 but
absent in the age group 45–54 years of age; the reason of
that observation could be a small number of analysed
specimens in these age groups. Further analysis with
larger number of samples is needed in these age groups.
In conclusion, the distribution of HPV infections
among Croatian women is similar to most countries with
HPV 16 being the most prevalent type followed by HPV
31 in precancerous lesions. HPV 33, 18 and 52 are all at
the third place of prevalence in this study group, while
HPV 45 and 58 remain low abundant HR HPV types. As
HPV detection of HR types is recommended for women
with equivocal cytology and for follow-up after treatment
of high-grade cervical lesions according to the Croatian di-
agnostic and therapeutic guidelines for management of
women with premalignant cervical lesions28, we suggest to
perform HPV typing for HR HPV types: 16, 18, 31, 33, 45,
52 and 58 in HPV positive women in order to improve the
monitoring process and prevent the cancer development.
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RETROSPEKTIVNA ANALIZA U^ESTALOSTI VISOKORIZI^NIH TIPOVA HUMANOG
PAPILOMAVIRUSA (HPV) KOD @ENA U HRVATSKOJ
S A @ E T A K
Infekcija humanim papilomavirusom (HPV) glavni je uzrok raka vrata maternice. Postoji najmanje 15 visokori-
zi~nih tipova HPV-a koji su zna~ajno povezani s napredovanjem cervikalne intraepitelne neoplazije (CIN) prema raku
vrata maternice. Budu}i da su prija{nje studije pokazale da je u~estalost HPV-a razli~ita me|u razli~itim zemljopisnim
podru~jima, na{ cilj je bio ispitati u~estalost tipova HPV-a u Hrvatskoj, posebno rijetkih visokorizi~nih tipova HPV-a.
Metodom lan~ane reakcije polimerazom (PCR), pomo}u konsenzus po~etnica, a kako bismo ustanovili prisutnost in-
fekcije HPV-om, analizirali smo uzorke DNK 2.136 `ena u Hrvatskoj, uglavnom s abnormalnim nalazom brisa vrata
maternice. Tip-specifi~ne po~etnice kori{tene su za detekciju sljede}ih tipova HPV-a: niskorizi~nih 6/11 te visokori-
zi~nih 16, 18, 31, 33, 45, 52 i 58. Od ukupno 2.136 uzoraka, 1.255 (58,8%) je bilo pozitivno, a 881 (41,3%) uzorak je bio
negativan na prisutnost nekog tipa HPV-a. Vi{e od polovine pozitivnih uzoraka bilo je tipizirano (64,5%), dok kod 35,5%
nije utvr|en tip HPV-a. Vi{estruke infekcije HPV-om su prona|ene u 10,3% slu~ajeva. Utvr|eno je da je naju~estaliji tip
HPV 16 s u~estalo{}u od 15,9%, uklju~uju}i jednostruke i vi{estruke infekcije. Slijedili su ga tipovi HPV-a: 31, 6/11, 33,
18, 52, 45 te 58 s 8,7%, 7,1%, 4,5%, 3,8%, 2,3%, 1,8% te 1,1% u~estalosti. Uo~eno je zna~ajno pove}anje u~estalosti od
blagih (LSIL, engl. Low-grade Squamous Intraepithelial Lesions) do te`ih (HSIL, High-grade Squamous Intraepithelial
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Lesions) promjena vrata maternice za visokorizi~ne tipove HPV-a 16, 18, 31 i 33, ali ne i za HPV 45, 52 i 58. U~estalost
nepoznatih tipova HPV-a (HPV X) bila je gotovo jednaka u uzorcima vrata maternice `ena sa citolo{kom dijagnozom
LSIL i HSIL, 19,8% i 21,1%. Uo~eno je zna~ajno smanjenje broja HPV-a s porastom dobi ispitanica, od 68,5% (dobna
skupina od 12 do 24 godine) prema 38,8% (dobna skupina od 45 to 54 godine). Me|utim, kod `ena od 55 godina i starijih
ukupna u~estalost infekcija HPV-om je porasla na 56,6%. Ovi rezultati u~estalosti visokorizi~nih tipova HPV-a u Hr-
vatskoj se podudaraju s onima zabilje`enim u drugim zemljama. Smatramo va`nim HPV-pozitivne `ene u Hrvatskoj
tipizirati barem na prisustvo visokorizi~nih tipova HPV-a: 16, 18, 31, 33, 45, 52 i 58 kako bi im se pru`ila maksimalna
pozornost.
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